Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)

BMC Public Health

Volumn 10, Issue , 2010, Pages

  Pettersson, Billie ^a,b   Ambegaonkar, Baishali ^c   Sazonov, Vasilisa ^c   Martinell, Mats ^d   Stålhammar, Jan ^d   Wändell, Per ^e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Merck Sharp Dohme (Sweden)   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BLOOD; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SWEDEN; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME;

EID: 78649337433     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-737     Document Type: Article

References (47)

1. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. P Greenland MD Knoll J Stamler JD Neaton AR Dyer DB Garside PW Wilson, JAMA 2003 290 891 897 10.1001/jama.290.7.891 12928465
2. Prevalence of conventional risk factors in patients with coronary heart disease. UN Khot MB Khot CT Bajzer SK Sapp EM Ohman SJ Brener SG Ellis AM Lincoff EJ Topol, JAMA 2003 290 898 904 10.1001/jama.290.7.898 12928466
3. Public Health Report 2009. Stockholm. The National Board of Health and Welfare, 2009
4. European cardiovascular disease statistics 2008. London. University of Oxford, 2008
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 1383 1389 7968073
6. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino A Kirby T Sourjina R Peto R Collins R Simes, Lancet 2005 366 1267 1278 10.1016/S0140-6736(05)67394-1 16214597
7. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. WP Castelli, Can J Cardiol 1988 4 Suppl A 5A 10A 3179802
8. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. DJ Gordon JL Probstfield RJ Garrison JD Neaton WP Castelli JD Knoke DR Jacobs Jr S Bangdiwala HA Tyroler, Circulation 1989 79 8 15 2642759
9. Cardiovascular disease risk profiles. KM Anderson PM Odell PW Wilson WB Kannel, Am Heart J 1991 121 293 298 10.1016/0002-8703(91)90861-B 1985385
10. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. G Assmann P Cullen H Schulte, Circulation 2002 105 310 315 10.1161/hc0302.102575 11804985
11. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. S Lewington G Whitlock R Clarke P Sherliker J Emberson J Halsey N Qizilbash R Peto R Collins, Lancet 2007 370 1829 1839 10.1016/S0140-6736(07) 61778-4 18061058
12. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. JE Hokanson MA Austin, J Cardiovasc Risk 1996 3 213 219 10.1097/00043798-199604000-00014 8836866
13. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. A Patel F Barzi K Jamrozik TH Lam H Ueshima G Whitlock M Woodward, Circulation 2004 110 2678 2686 10.1161/01.CIR.0000145542.24347.18 15492305
14. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. DR Chirovsky V Fedirko Y Cui V Sazonov P Barter, Eur J Cardiovasc Prev Rehabil 2009 16 404 423 10.1097/HJR.0b013e32832c8891 19465856
15. Medical Products Agency, Treatment Guidelines - Prevention of atherosclerotic cardiovascular disease Stockholm 2009
16. Cardiovascular morbidity and mortality associated with the metabolic syndrome. B Isomaa P Almgren T Tuomi B Forsen K Lahti M Nissen MR Taskinen L Groop, Diabetes Care 2001 24 683 689 10.2337/diacare.24.4.683 11315831
17. Small, dense low-density-lipoproteins and the metabolic syndrome. M Rizzo K Berneis, Diabetes Metab Res Rev 2007 23 14 20 10.1002/dmrr.694 17080469
18. Management of dyslipidemia in the metabolic syndrome. KC Tan, Cardiovasc Hematol Disord Drug Targets 2007 7 99 108 17584044
19. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. RB D'Agostino Sr S Grundy LM Sullivan P Wilson, Jama 2001 286 180 187 10.1001/jama.286.2.180 11448281
20. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. B Verges, Diabetes 2005 31 429 439
21. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. E Bruckert M Baccara-Dinet F McCoy J Chapman, Curr Med Res Opin 2005 21 1927 1934 10.1185/030079905X74871 16368042
22. Trends in blood pressure, lipids, lipoproteins and glucose metabolism in the Northern Sweden MONICA project 1986-99. JH Jansson K Boman T Messner, Scand J Public Health Suppl 2003 61 43 50 10.1080/14034950310001397 14660247
23. Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. P Lindgren F Borgstrom J Stalhammar E Alemao L Jonsson, Int J Clin Pract 2007 61 1410 1414 10.1111/j.1742-1241.2007.01468.x 17627716
24. The Vasterbotten Intervention Programme: background, design and implications. M Norberg S Wall K Boman L Weinehall, Glob Health Action 2010 3
25. Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. M Eliasson U Janlert JH Jansson B Stegmayr, J Intern Med 2006 260 551 559 10.1111/j.1365-2796.2006.01730.x 17116006
26. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. E Van Ganse L Laforest T Burke H Phatak T Souchet, Clin Ther 2007 29 1671 1681 10.1016/j.clinthera.2007.08.003 17919548
27. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. RS Birjmohun BA Hutten JJ Kastelein ES Stroes, J Am Coll Cardiol 2005 45 185 197 10.1016/j.jacc.2004.10.031 15653014
28. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. H Phatak C Wentworth V Sazonov T Burke, Atherosclerosis 2009 202 225 233 10.1016/j.atherosclerosis.2008.03.016 18457840
29. High Prevalence of Persistent Lipid Abnormalities in High-risk Patients Treated with Statins in Sweden - Results from the Dyslipidemia International Study (DYSIS) [abstract]. G Journath A Bröijersén P Lundman, XIth Swedish Cardiovascular Spring meeting 2009
30. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. P Lindgren F Borgstrom J Stalhammar E Alemao DD Yin L Jonsson, Eur J Cardiovasc Prev Rehabil 2005 12 530 534 10.1097/00149831-200512000-00003 16319541
31. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. GA Nichols BM Ambegaonkar V Sazonov JB Brown, Am J Cardiol 2009 104 1689 1694 10.1016/j.amjcard.2009.07.050 19962476
32. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 3143 3421 12485966
33. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone, J Am Coll Cardiol 2004 44 720 732 10.1016/j.jacc.2004.07.001 15358046
34. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. MJ Chapman, Cardiovasc Drugs Ther 2005 19 135 139 10.1007/s10557-005-1049-z 16025232
35. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. CP Cannon E Braunwald CH McCabe DJ Rader JL Rouleau R Belder SV Joyal KA Hill MA Pfeffer AM Skene, N Engl J Med 2004 350 1495 1504 10.1056/NEJMoa040583 15007110
36. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. TR Pedersen O Faergeman JJ Kastelein AG Olsson MJ Tikkanen I Holme ML Larsen FS Bendiksen C Lindahl M Szarek J Tsai, JAMA 2005 294 2437 2445 10.1001/jama.294.19.2437 16287954
37. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). H Bloomfield Rubins J Davenport V Babikian LM Brass D Collins L Wexler S Wagner V Papademetriou G Rutan SJ Robins, Circulation 2001 103 2828 2833 11401940
38. Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. N Goldenberg C Glueck, Vasc Health Risk Manag 2009 5 369 376 19475774
39. CBE, Extent and casues of international variations in drug usage. London 2010
40. Rand Corporation Europe, International variation in the usage of medicines-A review of the litterature Cambridge 2010
41. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? PM Ridker, Clin Chem 2008 54 11 13 10.1373/clinchem.2007.097907 17998265
42. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. RM Conroy K Pyorala AP Fitzgerald S Sans A Menotti G De Backer D De Bacquer P Ducimetiere P Jousilahti U Keil,, et al. Eur Heart J 2003 24 987 1003 10.1016/S0195-668X(03)00114-3 12788299
43. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. K Wolf-Maier RS Cooper JR Banegas S Giampaoli HW Hense M Joffres M Kastarinen N Poulter P Primatesta F Rodriguez-Artalejo,, et al. Jama 2003 289 2363 2369 10.1001/jama.289.18.2363 12746359
44. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. CL de Visser HJ Bilo TF Thomsen KH Groenier B Meyboom-de Jong, J Intern Med 2003 253 553 562 10.1046/j.1365-2796.2003.01137.x 12702033
45. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. TF Thomsen D McGee M Davidsen T Jorgensen, Int J Epidemiol 2002 31 817 822 10.1093/ije/31.4.817 12177028
46. The Dental and Pharmaceutical Benefits Agency, Genomgången av läkemedel vid blodfettsrubbningar Stockholm 2009
47. [The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus]. L Januszkiewicz, Kardiol Pol 2010 68 853 854 discussion 855 20648456